Have a heart, it's V-Day!

It's that time of year again...Valentine's Day! In honor of that, Seeking Alpha put together some nice data on 6 companies that work in the cardiac device market and in the website's opinion are making the right decisions. The basic take home message: Abbott and Edwards Life Sciences look like the strongest buys of the six.

Check it out for yourself!

Cadence Pharmaceuticals will have to wait just a big longer before it's IV acetaminophen his the market. The NDA was sent back to the company after "deficiencies" were noted by the FDA at the company's drug manufacturing facility. I think this is just a minor bump in the road, and that the drug itself represents an unmet need in the market for treating not just pain, but also fever in patients who can't take pills. Look for Cadence to resubmit as soon as the problems are ironed out and an approval to follow thereafter....

Here's the Cadence press release, courtesy of Fierce Biotech

Roche has announced some very promising results of late stage trials for its new Type 2 Diabetes drug taspoglutide, which could translate into a potential blockbuster if the drug makes it to market. This drug would be the first weekly GLP-1 analogue treatment available and would be a new treatment option for diabetics who could potentially control blood sugar levels with a once weekly treatment of this new medication. Watch this one closely as new effective diabetic treatments always generate a lot of press...

Business Week reports on the Roche's results at this link

Finally Cephalon reported last week that it had a substantial increase in 4th quarter profits...pretty impressive considering the state of the bioech market. You can chalk that up to increased sales for almost every marketed drug and with Nuvigil jumping fully on board in 2010, this trend may continue.

Read more at this AP article via Yahoo! Finance